Dear Friend,
With due respects to the views expressed by our learned friends, I respectfully submit that I have a different view on this issue.
Firstly the issue is reimbursement of the expenses incurred by foreign subsidiary for payment of regulatory fees ( product Registration etc.,) to the government of a particular country with regard to Registration and marketing of the products in that particular country /countries.
As already stated , the subsidiary abroad is treated as a distinct person for the purposes of Service Tax.
any amount paid as fees for such statutory functions, though reimbursed, is liable for ST under reverse charge mechanism more specifically from 1.4.2016 in view of deletion of certain services provided by Government deleted from the negative list.
You may also pl. refer the decision of Mumbai CESTAT reported in TMI under citation 2016 (4) TMI 111 - CESTAT MUMBAI,where the Hon'ble CESTAT held that ST is not payable on the fees paid to US FDA and oather Regulatory Authorities ( this issue related prior to 01.04.2016).
In view of the above, I am of the considered view that the subject expences are liable to ST under Reverse charge Mechanism.
Best Regards
Suryanarayana